

Disclosure of Potential Interests - Trustees (2011)

It should be noted that the senior officers (including the Trustee and Executive members) have regular contact with the Renal Association Corporate Members.

Name	Personal Interests	Honoraria	Connections
Charlie Tomson	I hold no shares or any other interests in any such companies	For at least the last 5 years I have received no honoraria, speaking fees, research grants or travel grants from any company	The department recruited patients for the SHARP study, which was an investigator led study funded directly by Merck. The department recruited two patients to the EVOLVE study, funded by Amgen
Peter Mathieson	None	I received an honorarium from Astellas in 2010 for reviewing work presented at the American Society of Nephrology	My research group has collaborative agreements with Eli-Lilly, Pfizer, Astellas, Evotech, Shionogi, Reata and GSK.
David Wheeler	Neither I nor my wife knowingly own shares in any pharmaceutical, biotechnological or medical device company.	During the period April 2010 up to June 2011 when I became President Elect, I received honoraria from Amgen and Shire Pharmaceuticals for giving lectures at scientific meetings. I also received consultancy fees from Amgen for my role as member of the International Steering Committee of the ARD project. Over this period, I have had expenses refunded by Amgen to cover travel to two ARD Committee Meetings and one EVOLVE investigator meeting.	I am the Chief Investigator on a Genzyme Renal Innovations Program Grant entitled "P2X7 purinoreceptor: A novel target for ameliorating vascular calcification". A PhD student that I supervise has received 12 months funding from Abbott to examine the prevalence of vitamin D deficiency in kidney transplant recipients. The annual dialysis course run by the UCL Centre for Nephrology (of which I am a director) receives support from various Pharmaceutical Companies.
Lorraine Harper	None	Honoraria from Novartis for travel. Unrestricted research grant from Novartis to perform Investigator led clinical trial. Consultancy work for GSK. Honoraria for travel from Amgen.	Investigator led studies funded by Novartis, Fujisawa and Baxter.
Jonathan Fox	None	None	None
Damian Fogarty	No declaration received	No declaration received	No declaration received
Bruce Hendry	None	2010 and 2011 Honoraria for Advisory Board work from Abbott Laboratories and Viviv Pharmaceuticals. Honoraria for lectures at Educational meetings from Gilead Sciences.	Collaborative research with isis Pharmaceuticals with supply of materials (not funding).
Martin Raftery	I have no shares in any company that might conflict with the RA other than as PEP's or ISA's over which I have no control.	I have received honoraria from the following companies for participating in Advisory Boards: Baxter UK, Novartis UK, Dexcel Pharma. I have received grants for registration, accommodation and travel expenses from the following to attend the ASN, WCN and ISN meetings over the past 3 years: Roche UK, Amgen UK, Astellas UK, Novartis UK	Our department has received grants for investigator led studies and Pharmaceutical led studies from the following companies: Amgen UK, Novartis UK, Astellas UK, Roche UK, Dexcel Pharma and Genzyme UK. All negotiations and contracts have been administered by the combined NHS Trust and Medical School R&D Department.
Mary McGraw	None	None	None